Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 27 of 51

26 Clinical OMICs January/February 2018 Chris Anderson Editor in Chief Pharmacogenomics Makes Inroads to the Clinical Setting Right Person Right Drug T he concept of variable patient response to medication is nearly 2,500 years old, first proposed by the father of modern medicine, Hippocrates, in his work the Hippocratic Corpus. While Hippocrates' method relied on what could be deter- mined in his day—patient age and condition—today, the detection of genetic variation between patients increasingly allows doctors to apply this knowledge in the selection and the dosing of medications for patients based on their molecular makeup. Pharmacogenomics—the use of genomic information to personalize drug selec- tion and dosing—is still relatively rare in the clinical setting. But that is beginning to change through the efforts of clinical pioneers—among them St. Jude Children's Research Hospital, in Memphis, TN, and the Mayo Clinic—and international coali- tions such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), that are spearheading efforts to provide both pharmacogenomics-based clinical guidelines, as well as evidence of improved patient outcomes via its application. The opportunity to positively impact patient care is significant. CPIC estimates 95% of people have at least one clinically actionable genetic variant that affects drug response (Richard Weinshilboum, M.D., and his team at the Mayo Clinic Center for Individualized Medicine's Pharmacogenomics Program estimate it is as high as 99%). "The focus and awareness of precision medicine really opens up pharmacogenetics in the clinical setting," said Ulrich Bro- eckel, M.D., a professor of pediatrics at Medical College of Wisconsin, and founder and CEO of fledgling phar- macogenetics testing company RPRD Diagnostics. Some of the push toward this is coming directly from patients, Broeckel noted, as their knowledge of genetic testing has increased due to the marketing efforts of direct-to-consumer genetic testing com- panies like and 23andMe. "The general population of patients recog- nizes the importance of genetics, and the added emphasis on precision medicine really raises the Jayk7 / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018